Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia

Journal of Proteomics

Volumn 99, Issue , 2014, Pages 54-67

  Datta, Arnab ^a   Qian, Jingru ^b   Chong, Ruifen ^a   Kalaria, Raj N ^c   Francis, Paul ^d   Lai, Mitchell K P ^a,e   Chen, Christopher P ^a,e   Sze, Siu Kwan ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Clinical proteomics; ITRAQ; Mass spectrometry; Oxidative stress; Vascular dementia; Vascular dysfunction

Indexed keywords

CLINICAL PROTEOMICS; ITRAQ; MASS SPECTROMETRY; OXIDATIVE STRESS; VASCULAR DEMENTIA; VASCULAR DYSFUNCTION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; NERVE TISSUE PROTEINS; PROTEOME; PROTEOMICS;

EID: 84893725125     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.01.011     Document Type: Article

References (45)

1. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., et al. Vascular cognitive impairment. Lancet Neurol 2003, 2:89-98.
2. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008, 7:812-826.
3. Kirvell S.L., Elliott M.S., Kalaria R.N., Hortobagyi T., Ballard C.G., Francis P.T. Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology 2010, 75:1803-1809.
4. Elliott M.S., Ballard C.G., Kalaria R.N., Perry R., Hortobagyi T., Francis P.T. Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain 2009, 132:1858-1865.
5. Clare R., King V.G., Wirenfeldt M., Vinters H.V. Synapse loss in dementias. J Neurosci Res 2010, 88:2083-2090.
6. Roman G., Pascual B. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia. Arch Med Res 2012, 43:671-676.
7. Kalaria R.N. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 2012, 43:2526-2534.
8. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169.
9. Zellner M., Veitinger M., Umlauf E. The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol 2009, 118:181-195.
10. Korolainen M.A., Nyman T.A., Aittokallio T., Pirttilä T. An update on clinical proteomics in Alzheimer's research. J Neurochem 2010, 112:1386-1414.
11. Datta A., Park J.E., Li X., Zhang H., Ho Z.S., Heese K., et al. Phenotyping of an in vitro model of ischemic penumbra by iTRAQ-based shotgun quantitative proteomics. J Proteome Res 2010, 9:472-484.
12. Datta A., Jingru Q., Khor T.H., Teo M.T., Heese K., Sze S.K. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. J Proteome Res 2011, 10:5199-5213.
13. Datta A., Akatsu H., Heese K., Sze S.K. Quantitative clinical proteomic study of autopsied human infarcted brain specimens to elucidate the deregulated pathways in ischemic stroke pathology. J Proteomics 2013, 10.1016/j.jprot.2013.08.017.
14. Gemmell E., Bosomworth H., Allan L., Hall R., Khundakar A., Oakley A.E., et al. Hippocampal neuronal atrophy and cognitive function in delayed poststroke and aging-related dementias. Stroke 2012, 43:808-814.
15. Kalaria R.N., Kenny R.A., Ballard C.G., Perry R., Ince P., Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004, 226:75-80.
16. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993, 43:250-260.
17. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
18. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
19. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
20. Weinkauf M., Hiddemann W., Dreyling M. Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background. Electrophoresis 2006, 27:4555-4558.
21. Chong P.K., Gan C.S., Pham T.K., Wright P.C. Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: implication of multiple injections. J Proteome Res 2006, 5:1232-1240.
22. Wessel D., Flugge U.I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984, 138:141-143.
23. Schmidt S.A., Jacob S.S., Ahn S.B., Rupasinghe T., Krömer J.O., Khan A., et al. Two strings to the systems biology bow: co-extracting the metabolome and proteome of yeast. Metabolomics 2013, 9:173-188.
24. Zhang H., Guo T., Li X., Datta A., Park J.E., Yang J., et al. Simultaneous characterization of glyco- and phosphoproteomes of mouse brain membrane proteome with electrostatic repulsion hydrophilic interaction chromatography. Mol Cell Proteomics 2010, 9:635-647.
25. Hao P., Guo T., Li X., Adav S.S., Yang J., Wei M., et al. Novel application of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) in shotgun proteomics: comprehensive profiling of rat kidney proteome. J Proteome Res 2010, 9:3520-3526.
26. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003, 13:2129-2141.
27. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
28. Mohamed N.E., Zhao Y., Lee J.H., Tan M.G., Esiri M.M., Wilcock G.K., et al. Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. Neurochem Int 2011, 58:820-825.
29. Simpson J.E., Hosny O., Wharton S.B., Heath P.R., Holden H., Fernando M.S., et al. Microarray RNA expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways. Stroke 2009, 40:369-375.
30. Crecelius A., Götz A., Arzberger T., Fröhlich T., Arnold G.J., Ferrer I., et al. Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 2008, 8:1276-1291.
31. Esiri M.M., Nagy Z., Smith M.Z., Barnetson L., Smith A.D., Joachim C. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999, 354:919-920.
32. Lammie G.A. Pathology of small vessel stroke. Br Med Bull 2000, 56:296-306.
33. Taheri S., Gasparovic C., Huisa B.N., Adair J.C., Edmonds E., Prestopnik J., et al. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 2011, 42:2158-2163.
34. Akiguchi I., Tomimoto H., Suenaga T., Wakita H., Budka H. Blood-brain barrier dysfunction in Binswanger's disease; an immunohistochemical study. Acta Neuropathol 1998, 95:78-84.
35. 1H MR spectroscopy. AJNR Am J Neuroradiol 2000, 21:621-630.
36. Hojer-Pedersen E., Petersen O.F. Changes of blood flow in the cerebral cortex after subcortical ischemic infarction. Stroke 1989, 20:211-216.
37. Geraci F., Turturici G., Sconzo G. Hsp70 and its molecular role in nervous system diseases. Biochem Res Int 2011, 18. [Hindawi Publishing Corporation] [Article ID 618127]. 10.1155/2011/618127.
38. Strekalova H., Buhmann C., Kleene R., Eggers C., Saffell J., Hemperly J., et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging 2006, 27:1-9.
39. Guo H., Tong N., Turner T., Epstein L.G., McDermott M.P., Kilgannon P., et al. Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury. Ann Neurol 2000, 48:590-602.
40. Tian L., Lappalainen J., Autero M., Hanninen S., Rauvala H., Gahmberg C.G. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 2008, 111:3615-3625.
41. Bartzokis G., Tishler T.A., Lu P.H., Villablanca P., Altshuler L.L., Carter M., et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 2007, 28:414-423.
42. Schröder N., Figueiredo L.S., De Lima M.N.M. Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies. J Alzheimers Dis 2013, 34:797-812.
43. Kinouchi H., Epstein C.J., Mizui T., Carlson E., Chen S.F., Chan P.H. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci U S A 1991, 88:11158-11162.
44. Sakata H., Niizuma K., Wakai T., Narasimhan P., Maier C.M., Chan P.H. Neural stem cells genetically modified to overexpress Cu/Zn-superoxide dismutase enhance amelioration of ischemic stroke in mice. Stroke 2012, 43:2423-2429.
45. Gray F., Polivka M., Viswanathan A., Baudrimont M., Bousser M.G., Chabriat H. Apoptosis in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Neuropathol Exp Neurol 2007, 66:597-607.